Drug Profile
Research programme: human monoclonal antibodies - Abgenix/Biogen Idec
Latest Information Update: 23 Feb 2005
Price :
$50
*
At a glance
- Originator Abgenix; Biogen Idec
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Inflammation; Neurological disorders
Most Recent Events
- 22 Feb 2005 No development reported - Preclinical for Inflammation in USA (unspecified route)
- 22 Feb 2005 No development reported - Preclinical for Cancer in USA (unspecified route)
- 22 Feb 2005 No development reported - Preclinical for Neurological disorders in USA (unspecified route)